Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Существуют ли перспективы применения петлевых диуретиков для лечения артериальной гипертензии?
Существуют ли перспективы применения петлевых диуретиков для лечения артериальной гипертензии?
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Обсуждаются показания к применению петлевых диуретиков для лечения артериальной гипертензии и ограничения, существующие в настоящее время с точки зрения их внедрения в практику рутинной антигипертензивной терапии. На примере торасемида продемонстрированы перспективы применения петлевых диуретиков для лечения артериальной гипертензии.
Ключевые слова: петлевые диуретики, артериальная гипертензия, торасемид, антигипертензивная терапия.
Key words: loop diuretics, essential hypertension, torasemide, antihypertensive therapy.
Ключевые слова: петлевые диуретики, артериальная гипертензия, торасемид, антигипертензивная терапия.
________________________________________________
Key words: loop diuretics, essential hypertension, torasemide, antihypertensive therapy.
Полный текст
Список литературы
1. Диагностика и лечение артериальной гипертензии. Системные гипертензии. Комитет экспертов РМОАГ/ВНОК. 2010; 3: 5–26.
2. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131: 1949–62.
3. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health 1988; 78: 636–40.
4. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных частыми гипертоническими кризами. Тер. арх. 2009; 9: 9–12.
5. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008; 19: 1845–54.
6. Kalaitzidis R, Li S, Wang C et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53 (Suppl. 4): 22–31.
7. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134 (8): 629–36.
8. Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131 (2): 350–5.
9. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
10. Russo D, Gazzotti RM, Testa A. Torasemide, a new loop diuretic, in patients with chronic renal failure. Nephron 1990; 55 (2): 141–5.
11. Fliser D, Schröter M, Neubeck M et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46 (2): 482–8.
12. Gehr TW, Rudy DW, Matzke GR et al. The pharmacokinetics of intravenous and oral torasemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56 (1): 31–8.
13. Risler T, Schwab A, Kramer B et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology 1994; 84 (Suppl. 2): 155–61.
14. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45–50.
15. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002; 8: 18–22.
16. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
17. López B, González A, Hermida N et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl 2008; 111: 19–23.
18. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Mosso L, Carvajal C, Gonzales A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
20. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48 (11): 2293–300.
21. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–42.
22. Born-Frontsberg E, Reincke M, Rump LC et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94 (4): 1125–30.
23. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
24. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension 2007; 49: 839–45.
25. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
26. Handler J. Maximizing diuretic therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9 (10): 802–6.
2. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131: 1949–62.
3. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health 1988; 78: 636–40.
4. Колос И.П., Чазова И.Е., Терещенко С.Н., Наконечников С.Н. Риск сердечно-сосудистых осложнений у больных частыми гипертоническими кризами. Тер. арх. 2009; 9: 9–12.
5. Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008; 19: 1845–54.
6. Kalaitzidis R, Li S, Wang C et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53 (Suppl. 4): 22–31.
7. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134 (8): 629–36.
8. Kostis JB, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131 (2): 350–5.
9. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
10. Russo D, Gazzotti RM, Testa A. Torasemide, a new loop diuretic, in patients with chronic renal failure. Nephron 1990; 55 (2): 141–5.
11. Fliser D, Schröter M, Neubeck M et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46 (2): 482–8.
12. Gehr TW, Rudy DW, Matzke GR et al. The pharmacokinetics of intravenous and oral torasemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56 (1): 31–8.
13. Risler T, Schwab A, Kramer B et al. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology 1994; 84 (Suppl. 2): 155–61.
14. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): 45–50.
15. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002; 8: 18–22.
16. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
17. López B, González A, Hermida N et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl 2008; 111: 19–23.
18. López B, González A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50 (9): 859–67.
19. Mosso L, Carvajal C, Gonzales A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
20. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48 (11): 2293–300.
21. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–42.
22. Born-Frontsberg E, Reincke M, Rump LC et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 2009; 94 (4): 1125–30.
23. Berecek KH, Farag A, Bahtiyar G et al. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep 2004; 6 (3): 211–2.
24. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension 2007; 49: 839–45.
25. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000; 61 (1): 52–60.
26. Handler J. Maximizing diuretic therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9 (10): 802–6.
Авторы
В.В.Фомин
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
fomin_vic@mail.ru
I.M.Sechenov First Moscow State Medical University, Ministry of Health and Social Development of Russia
fomin_vic@mail.ru
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
fomin_vic@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University, Ministry of Health and Social Development of Russia
fomin_vic@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.